Clinical studies showed that ER + PR + breast cancer shows a better response to endocrine therapy, whereas ER + PR- breast carcinoma has a more aggressive phenotype and a poorer response to endocrine therapy. This evidence concerns the gene ESR1 and breast carcinoma.